177 related articles for article (PubMed ID: 38114391)
1. SOHO State of the Art Updates and Next Questions: Oral Therapy in Acute Myeloid Leukemia.
Nasnas P; Ravandi F
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):205-213. PubMed ID: 38114391
[TBL] [Abstract][Full Text] [Related]
2. SOHO State of the Art Updates and Next Questions |The Role of Maintenance Therapy in Acute Myeloid Leukemia.
Babakhanlou R; Ravandi-Kashani F
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):1-7. PubMed ID: 36456394
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
4. SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML.
Inguva A; Pollyea DA
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):805-811. PubMed ID: 34389272
[TBL] [Abstract][Full Text] [Related]
5. SOHO State of the Art Updates and Next Questions:Harnessing Apoptosis in AML.
Saxena K; DiNardo C; Daver N; Konopleva M
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):133-139. PubMed ID: 34602371
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in targeted therapies in acute myeloid leukemia.
Bhansali RS; Pratz KW; Lai C
J Hematol Oncol; 2023 Mar; 16(1):29. PubMed ID: 36966300
[TBL] [Abstract][Full Text] [Related]
8. CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML.
Molica M; Perrone S; Mazzone C; Cesini L; Canichella M; de Fabritiis P
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740508
[TBL] [Abstract][Full Text] [Related]
9. The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia.
Briski R; Garcia-Manero G; Kantarjian H; Ravandi F
Ther Adv Hematol; 2023; 14():20406207231205429. PubMed ID: 37854355
[TBL] [Abstract][Full Text] [Related]
10. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
DiNardo CD; Stein EM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
[TBL] [Abstract][Full Text] [Related]
11. SOHO State of the Art Updates and Next Questions-WHO Classification of Acute Myeloid Leukemia.
Loghavi S
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38866644
[TBL] [Abstract][Full Text] [Related]
12. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
[TBL] [Abstract][Full Text] [Related]
13. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
Garcia-Manero G; Döhner H; Wei AH; La Torre I; Skikne B; Beach CL; Santini V
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):236-250. PubMed ID: 34758945
[TBL] [Abstract][Full Text] [Related]
14. [Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
Ma XR; Wang J; Zhang WG; Chen YX; Cao XM; He AL; Liu J; Wang JL; Gu LF; Lei B; Zhang PY; Zhao WH; Yang Y; Wang FX; Xu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):369-74. PubMed ID: 25948187
[TBL] [Abstract][Full Text] [Related]
15. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
Chen EC; Fathi AT; Brunner AM
Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134
[TBL] [Abstract][Full Text] [Related]
16. New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S; Eskazan AE
Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.
Brown P; Smith FO
Paediatr Drugs; 2008; 10(2):85-92. PubMed ID: 18345718
[TBL] [Abstract][Full Text] [Related]
18. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
19. The incidence of secondary leukemias.
Leone G; Mele L; Pulsoni A; Equitani F; Pagano L
Haematologica; 1999 Oct; 84(10):937-45. PubMed ID: 10509043
[TBL] [Abstract][Full Text] [Related]
20. Advances in acute myeloid leukemia differentiation therapy: A critical review.
Abdel-Aziz AK
Biochem Pharmacol; 2023 Sep; 215():115709. PubMed ID: 37506924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
